[First experience with retinoid acid derivative Ro 10-9359 in the treatment of viral epithelioma].
Two patients with extensive verrucae plantares have been treated successfully with the retinoic acid derivative Ro 10-9359. Both patients were practically unable to walk due to widespread involvement of the plantae pedium. In a second series of 12 patients with verrucae vulgares this form of therapy produced unsatisfactory results. In 2 further patients with verrucae plantares healing was achieved in one, and also in a patient with verrucae planae. A patient with verrucae periunguales did not react to the treatment. The dosage was gradually increased to above the normal value of 1.0 mg/kg body weight per day, according to individual tolerance. The aim was to reach a dose of over 1.5 mg/kg body weight per day. The side effects were therefore impressive and interruption or termination of therapy was often necessary. However, new side effects have not been observed with this high dosage and this new indication, apart from psoriasiform dermatitis and an intermittent vegetative disturbance, the latter without clear evidence of a causal relation to the Ro 10-9359 medication. Pathological liver values have not been observed. Treatment with retinoid appears to be appropriate in cases with verrucae plantares, especially where conventional methods do not prove satisfactory.
D000293:Adolescent; D000328:Adult; D005050:Etretinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005534:Foot Diseases / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014212:Tretinoin / Q000031:analogs & derivatives*; D014860:Warts / Q000188:drug therapy*
D014212:Tretinoin; D005050:Etretinate
Erste Erfahrungen mit dem Vitamin-A-Säure-Derivat Ro 10-9359 bei Virusepitheliomen.